BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260428T080000
DTEND;TZID=America/New_York:20260428T093000
DTSTAMP:20260422T202826
CREATED:20260413T153417Z
LAST-MODIFIED:20260422T154639Z
UID:2992-1777363200-1777368600@lifescievents.com
SUMMARY:Humacyte Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients
DESCRIPTION:Join Humacyte for a virtual key opinion leader (KOL) event featuring Prabir Roy-Chaudhury MD\, PhD\, FASN (University of North Carolina (UNC) Kidney Center\, Salisbury VA Medical Center)\, and Mohamad A. Hussain\, MD\, PhD\, RPVI\, FAHA\, FRCSC\, FACS (Brigham & Women’s Hospital\, Center for Surgery and Public Health\, Harvard Medical School)\, who will join company management to discuss the unmet need and current treatment landscape for hemodialysis patients with End-Stage Renal Disease (ESRD). \nThe event will provide an overview of the Company’s investigational Acellular Tissue Engineered Vessels (ATEV.) The current standard of care for providing AV access involves connecting the patient’s artery with a vein\, known as an arteriovenous fistula or AV fistula (AVF). Humacyte’s ATEV is designed to provide an alternative to the current standard of care for hemodialysis patients with ESRD\, as AVFs can take weeks or months to mature and become usable for hemodialysis\, and in many patients fail to mature at all. One Phase 3 trial has already been completed showing the superiority of the ATEV in AV Access compared to autologous AV fistula. Company management will also review the ongoing V012 Phase 3 trial in hemodialysis for which interim top-line results are expected this quarter. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/fns036m/.
URL:https://lifescievents.com/event/fns036m/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/Banners-14.png
END:VEVENT
END:VCALENDAR